A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension

NCT01104701 on ClinicalTrials.gov · last registry update 2015-08-20

Finished December 2010, after enrolling 121 people. Primary outcome, as filed: Mean Change in HbA1c From Baseline to End of Treatment (Week 20) - Evaluable Population. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: AstraZeneca
Sponsor type: Industry
Enrollment: 121
Started: 2010-05
Primary completion: 2010-12 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Mean Change in HbA1c From Baseline to End of Treatment (Week 20) - Evaluable Population

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.